• Medientyp: E-Artikel
  • Titel: Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy
  • Beteiligte: Docherty, Kieran F.; Jhund, Pardeep S.; Bengtsson, Olof; DeMets, David L.; Inzucchi, Silvio E.; Køber, Lars; Kosiborod, Mikhail N.; Langkilde, Anna Maria; Martinez, Felipe A.; Sabatine, Marc S.; Sjöstrand, Mikaela; Solomon, Scott D.; McMurray, John J.V.; Diez, Mirta; Sassone, Sonia; Aizenberg, Diego; Talavera, Maria; Mercau, Guillermo; Martinez, Diego; Albisu, Juan; Hershson, Alejandro; GarcíaDurán, Rubén; Hominal, Miguel; Cluigt, Natalia; [...]
  • Erschienen: American Diabetes Association, 2020
  • Erschienen in: Diabetes Care
  • Sprache: Englisch
  • DOI: 10.2337/dc20-1402
  • ISSN: 0149-5992; 1935-5548
  • Schlagwörter: Advanced and Specialized Nursing ; Endocrinology, Diabetes and Metabolism ; Internal Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang